Segments - Europe In Vitro Diagnostics Market by Products (Instruments, Reagents, and Services), Techniques (Immunology, Hematology, Clinical Chemistry, Coagulation, Microbiology, and Molecular Diagnostics), Applications (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others), End-users (Hospitals, Laboratories, and Home Care), and Geography (Germany, the UK, France, the Netherlands, and Rest of Europe) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The Europe in vitro diagnostics market size was USD 15.91 Billion in 2022 and is projected to reach USD 24.26 Billion by 2031 expand at a substantial CAGR 4.8% during the forecast period, 2023–2031. The growth of the market is attributed to the wide prevalence of chronic diseases as well as growing public awareness regarding early detection of life-threatening diseases.
Medical devices, assays, and reagents are key components for in vitro diagnostics (IVD) process, which are used to diagnose a medical condition. Various instruments are also used to analyze tissue samples and bodily fluids obtained from patients and some of the key diagnostic instruments are immunodiagnostics, tissue diagnostics, and molecular diagnostics.
The diagnostics devices are also widely adopted for detecting various infectious diseases and chronic illness such as cardiac disorders, cancer, and diabetes. Furthermore, since the use and handling of in vitro diagnostics necessitates professional experience, diagnosis is carried out in specialist medical facilities using instruments. IVD materials, for example, are used in standalone labs, clinics, and point-of-care settings.
The elderly population is vulnerable to a variety of degenerative and infectious diseases, which is resulting in a wide occurrence of targeted diseases of this group of population. According to a report, the number of people aged 65 and above who are suffering from such diseases in Europe is projected to increase from 18.5 percent in 2014 to 28.7 percent in 2080. Since diagnostic interpretation is required for effective disease treatment, IVDs are important parts of the healthcare industry, especially in the diseases diagnosis.
The report on the Europe in vitro diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
In Vitro Diagnostics Market - Europe Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Products (Instruments, Reagents, and Services), Techniques (Immunology, Hematology, Clinical Chemistry, Coagulation, Microbiology, and Molecular Diagnostics), Applications (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Others), and End-users (Hospitals, Laboratories, and Home Care) |
Geographical Scope |
Germany, the UK, France, the Netherlands, and Rest of Europe |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Roche Diagnostics; Alere, Inc.; Abbott Laboratories, Inc.; Hologic, Inc.; (Gen-Probe), Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corporation; Becton, Dickinson (BD) Company Inc.; bioMerieux, Inc.; and Siemens Healthcare GmbH. |
Based on products, the Europe in vitro diagnostics market is divided into instruments, reagents, and services. The reagent segment is expected to represent a key share of the market and hold a dominant share during the forecast period. The segment growth is attributed to increasingly adoption of reagent in clinical laboratories, academic medical schools, research centers, and therapeutic areas.
On the basis of techniques, the market is divided into immunology, hematology, clinical chemistry, coagulation, microbiology, and molecular diagnostics. The molecular diagnostic segment is expected to grow at a rapid pace during the forecast period owing to its ability to diagnose various infectious and chronic diseases effectively and accurately.
Moreover, the increasing market penetration of instrument manufacturers in Asia Pacific and Latin America presents a crucial aspect for the segment growth.
Based on applications, the Europe in vitro diagnostics market is divided into infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and others. The cancer/oncology segment is expected to expand at a substantial CAGR during the forecast period due to the introduction of technologically advanced instruments and the increasing demand for companion diagnostics for various cancer treatment.
Meanwhile, the infectious diseases diagnostics market is projected to account for a large market share in the coming years due to the increasing prevalence of hospital-acquired infections and the high unmet medical needs for successful infectious disease diagnosis.
In terms of end-users, the market is divided into hospitals, laboratories, and home care. The home care segment is anticipated to constitute a major share of the market during the forecast period. The segment growth can be attributed to growing demand for rapid diagnostic services for patients at the time of care and rising government measures aiming at reducing hospital stays in order to reduce healthcare spending.
However, the hospitals segment is anticipated to exhibit a considerable growth rate during the projected period owing to high volume of IVD-based tests in hospitals.
On the basis of geography, the Europe in vitro diagnostics market is classified as Germany, the UK, France, the Netherlands, and Rest of Europe. The UK is a fast-growing market and is expected to hold a key market share during the forecast period owing to increasing demand for point-of-care and rapid-testing, especially blood glucose testing in the country.
Moreover, the strong government support to encourage early disease detection for the prevention of infectious diseases among its citizens of the country plays an important role for the market development in the region.
Germany, France, Italy, Spain, the UK, Belgium, Switzerland, Austria, the Netherlands, and Sweden accounted for more than 80% of the market share in 2020 owing to the involvement of a large number of main manufacturing firms such as Siemens Healthcare GmbH. Meanwhile, the high acceptance of these IVD technology in Germany is a major reason for owing for more than 15% of the regional market share in 2020.
The Europe in vitro diagnostics market has been segmented on the basis of
Key players competing in the Europe in vitro diagnostics market are Roche Diagnostics; Alere, Inc.; Abbott Laboratories, Inc.; Hologic, Inc.; (Gen-Probe), Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corporation; Becton, Dickinson (BD) Company Inc.; bioMerieux, Inc.; and Siemens Healthcare GmbH. Market players are funding their research and development activities in order to develop advanced technology that helps to improve current diagnostic process.